Aventis/Genta Genasense meeting confirmed
Date for review of Aventis/Genta's antisense drug Genasense by FDA's oncologic committee has been confirmed for May 3. Genta said it would receive an early May review by the committee (1"The Pink Sheet" Feb. 16, 2004, p. 6). The meeting will begin at 8 a.m. at the Hilton in Gaithersburg, Md...
You may also be interested in...
Aventis and Genta's antisense drug Genasense for treatment of advanced melanoma is expected to be reviewed by FDA's Oncologic Drugs Advisory Committee May 3
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the European Union, and updates on EU marketing authorization changes recommended by the CHMP.
Company is confident that data readout from pivotal trial could be ready before the end of 2020.